Molecular diagnostics company Xagenic nets $15 mln in new funding
Toronto-based molecular diagnostics company Xagenic Inc has secured a total of $15 million in follow-on funding. Each of the Canadian and U.S. investors in Xagenic's Series B financing, which had a second close at $25.5 million in July 2014, participated in the latest round. They included: Domain Associates, CTI Life Sciences Fund, BDC Capital and the Ontario Capital Growth Corp. Xagenic President and CEO Timothy I. Still said the new capital injection will help "accelerate our development efforts in bringing our point-of-care diagnostic platform to market.” The company was founded in 2010.
10 July 2015•4 mins read
